Cancer Treatment

Invasive lobular carcinoma

4 min read
Image of lungs

Invasive Lobular Carcinoma: A Comprehensive Overview of Diagnosis and Treatment

Invasive lobular carcinoma (ILC) is the second most common type of breast cancer, representing approximately 10 to 15% of all cases. Unlike invasive ductal carcinoma, which originates in the milk ducts, ILC begins in the milk-producing lobules of the breast. This type of cancer tends to be more difficult to detect through mammography and often presents with unique characteristics, which pose challenges for both diagnosis and treatment.

Epidemiology

ILC typically affects women over the age of 40, with the average age at diagnosis being 55 to 60 years old. Although ILC can occur in both premenopausal and postmenopausal women, it appears to be more commonly found in postmenopausal women. In terms of incidence, ILC is less frequent than invasive ductal carcinoma. However, it carries a higher risk of metastasis to other organs, such as the bones, ovaries, and peritoneum.

Diagnosis

Due to its unique characteristics, diagnosing ILC can be challenging. Mammograms, which are commonly used for breast cancer screening, may not always detect ILC. This is because ILC cells often grow in a single-file pattern rather than clumping together, making them less visible on mammograms. Imaging techniques such as ultrasound and magnetic resonance imaging (MRI) may be more effective in detecting ILC. However, the gold standard for diagnosis remains a biopsy, where a small sample of tissue is examined under a microscope to determine if cancer cells are present.

Treatment

The treatment of ILC typically involves a multidisciplinary approach, which may include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. The exact treatment plan will depend on several factors, including the size and stage of the tumor, the presence of hormone receptors, and the individual's overall health. Surgical options may range from lumpectomy, where only the tumor and surrounding tissue are removed, to mastectomy, where the entire breast is removed. Radiation therapy is often used after surgery to target any remaining cancer cells. Chemotherapy, hormone therapy, and targeted therapy may be used before or after surgery to reduce the risk of recurrence and metastasis.

Current Drugs for Invasive Lobular Carcinoma

Several drugs are currently used in the treatment of ILC:

  • Tamoxifen: A hormone therapy drug that blocks the effects of estrogen, commonly used in hormone receptor-positive ILC.
  • Letrozole: An aromatase inhibitor that decreases the production of estrogen, often prescribed as adjuvant therapy for postmenopausal women with hormone receptor-positive ILC.
  • Trastuzumab: A targeted therapy drug that specifically targets HER2-positive ILC, helping to block the growth and spread of cancer cells.
  • Palbociclib: A CDK4/6 inhibitor that restricts the division of cancer cells, often used in combination with hormone therapy for hormone receptor-positive ILC.

Promising Future Drugs in Clinical Trials

While existing drugs have shown significant efficacy in the treatment of ILC, ongoing clinical trials are exploring new therapies that hold potential for future treatment options. Some of the promising drugs being investigated include:

  • Abemaciclib: Another CDK4/6 inhibitor that has shown promise in early-stage trials for the treatment of ILC, particularly in combination with other drugs.
  • Tucatinib: A HER2 inhibitor that has demonstrated efficacy in HER2-positive breast cancer and is currently being evaluated in clinical trials for ILC.
  • Pembrolizumab: An immune checkpoint inhibitor that has shown promise in various cancer types and is now being tested in clinical trials for ILC.
  • Talazoparib: A PARP inhibitor that disrupts DNA repair in cancer cells and is showing potential for the treatment of ILC.

As these drugs continue to progress through late-stage clinical trials, they offer hope for improved outcomes and expanded treatment options for patients with ILC.

In conclusion, invasive lobular carcinoma presents unique challenges in diagnosis and treatment. Early detection through thorough imaging and accurate biopsy remains crucial for effective management. Current drugs, such as tamoxifen, letrozole, trastuzumab, and palbociclib, have revolutionized ILC treatment. However, ongoing clinical trials with drugs like abemaciclib, tucatinib, pembrolizumab, and talazoparib are promising for further advancements. With continued research and development, the future looks hopeful for individuals battling invasive lobular carcinoma.